Loading clinical trials...
Loading clinical trials...
STUDY OF THE EFFICACY AND SAFETY OF FIRST LINE TREATMENT WITH CHOP AND LENALIDOMIDE (Rev-CHOP) IN PATIENTS AGED FROM 60 TO 80 YEARS WITH PREVIOUSLY UNTREATED ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL)
Conditions
Interventions
Lenalidomide
Locations
30
Belgium
Université Catholique de Louvain Saint Luc
Brussels, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
Université Catholique de Louvain Mont Godinne
Yvoir, Belgium
CHU d'Amiens - Hôpital Sud
Amiens, France
CHU Angers
Angers, France
CH d'Avignon - Hôpital Henri Duffaut
Avignon, France
Start Date
November 1, 2011
Primary Completion Date
March 1, 2018
Completion Date
March 21, 2019
Last Updated
July 26, 2021
NCT07388563
NCT06561048
NCT05679895
NCT04752826
NCT06909877
NCT07356245
Lead Sponsor
The Lymphoma Academic Research Organisation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions